Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05485012 · ClinicalTrials.gov registry record · Phase 1
Reinforcing Effects of Marijuana and Opioids
A Phase 1 study, sponsored by Shanna Babalonis, PhD.
- Completed
- Registry status
- Phase 1
- Development phase
- 8
- Enrollment target
NCT05485012: Completed Phase 1 study, sponsored by Shanna Babalonis, PhD.
NCT05485012 is a Phase 1 study that has completed, run by Shanna Babalonis, PhD. The registered enrollment target is 8 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (87% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05485012, a Phase 1 study, has completed, sponsored by Shanna Babalonis, PhD.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 8 participants
- Enrollment target
Study Summary
The primary goals of this study are to examine 1) marijuana modulation of oxycodone self-administration and 2) oxycodone modulation of marijuana self-administration, under controlled conditions and across a range of doses for each drug.
Primary Outcome
The number of units of drug (out of a total of 7) earned in each experimental condition. Participants work for some, none, or all of the available drug dose. For each dose condition, the number of drug units completed for drug was pulled from the raw data and averaged to yield one mean (SEM).
Interventions
- DRUG Opioid
- DRUG Marijuana
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 8 participants |
| Start Date | 2023-08-03 |
| Est. Completion | 2025-03-27 |
| Phase | Phase 1 |
What the finished NCT05485012 record still lists
NCT05485012 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 8 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (87% lower).
The record links to 0 conditions, and to 2 interventions - of which Opioid is the first listed.
NCT05485012 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05485012 about?
NCT05485012 is a clinical study titled "Reinforcing Effects of Marijuana and Opioids". The primary goals of this study are to examine 1) marijuana modulation of oxycodone self-administration and 2) oxycodone modulation of marijuana self-administration, under controlled conditions and across a range of doses for each drug.
What is the current status of trial NCT05485012?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 8 participants. The study started on 2023-08-03. Estimated completion is 2025-03-27.
What interventions are being tested in trial NCT05485012?
The interventions under investigation include: Opioid (DRUG), Marijuana (DRUG).
Who is sponsoring clinical trial NCT05485012?
This trial is sponsored by Shanna Babalonis, PhD, which has 6 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT05485012's enrollment target sits among peer trials
8 1959th of 2000 higher than 29 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI